Andy McLean

Andy is the lead Life Sciences investor at Oxford Sciences Innovation (OSI), where he oversees a portfolio of 11 innovative life sciences companies. In this role, he was involved in seeding Evox Therapeutics, Vaccitech, and Lab282. Before joining OSI, Andy was a consultant in McKinsey & Company’s London office. He has a MBBS in Medicine and Surgery from the University of Western Australia and a BA (Hons) in Philosophy, Politics and Economics from the University of Oxford.